Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion

NCT03081481 is registered in ClinicalTrials.gov with Sophiris Bio Corp as lead sponsor.

NCT NCT03081481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03081481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Lead sponsor
Sophiris Bio Corp
Phase
Phase 2
Overall status
Completed
Start date
June 7, 2017
Completion date
April 5, 2019
Enrollment
38 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer